Table 2.
Treatment of juvenile idiopathic arthritis and inborn errors of immunity.
| Reference | Number of patients | IEI | Type of JIA | Treatment | Outcome | Side effects |
|---|---|---|---|---|---|---|
| Davies et al. (10) | 5 | 22q11.2DS | #1 polyarticular | #1 joint injection + MTX + CCS | #1 efficacious | #1 N/A |
| #2 polyarticular | #2 NSAID + HCQ + MTX | #2 efficacious | #2 N/A | |||
| #3 polyarticular | #3 CCS + MTX | #3 efficacious | #3 N/A | |||
| #4 polyarticular | #4 NSAID + CCS + MTX | #4 partial response | #4 N/A | |||
| #5 polyarticular | #5 NSAID + MTX | #5 partial response | #5 N/A | |||
| Rasmussen et al. (11) | 2 | 22q11.2DS | #1 polyarticular | #1N/A | #1 N/A | #1 N/A |
| #2 oligoarticular | #2 NSAID | #2 partial response | #2 N/A | |||
| Sullivan et al. (12) | 3 | 22q11.2DS | #1 polyarticular | #1 N/A | #1 N/A | #1 N/A |
| #2 oligoarticular | #2 NSAID | #2 efficacious | #2 N/A | |||
| #3 polyarticular | #3 NSAID + CCS + MTX | #3 partial response | #3 N/A | |||
| Patiroglu et al. (13) | 2 | XLA | #1 polyarticular | #1 SSZ + MTX + ETA + IVIG | #1 efficacious (IVIG) | #1Guillain–Barre syndrome (ETA) |
| #2 polyarticular | #2 MTX + IVIG | #2 efficacious (IVIG) | #2 | |||
| Vancsa et al. (14) | 2 | XLA | #1 polyarticular | #1 IVIG + NSAID + SSZ | #1 efficacious | #1 N/A |
| #2 polyarticular | #2 IVIG + NSAID + SSZ | #2 N/A | #2 N/A |
22q11.2DS, 22q11.2 deletion syndrome; CCS, corticosteroid; ETA, Etanercept; HCQ, hydroxychloroquine; IVIG, intravenous immunoglobulin; N/A, not assessed; SSZ, sulfasalazine; XLA, X-linked agammaglobulinemia.